Patent US3461583A successfully refreshed from Google Patents.
US5858744A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Retroviral vector hybrids and the use thereof for gene transfer
Assignee: Roche Diagnostics GmbH
•
Filing: 1995-08-10
•
Granted: 1999-01-12
•
Expires: 2015-08-10
Abstract
Abstract PCT No. PCT/EP95/03175 Sec. 371 Date Mar. 7, 1997 Sec. 102(e) Date Mar. 7, 1997 PCT Filed Aug. 10, 1995 PCT Pub. No. WO96/07747 PCT Pub. Date Mar. 14, 1996Replication-defective retroviral vector hybrids which are characterized in that they contain a) the U5 region and/or tRNA primer binding site of MESV as the U5 region and/or tRNA primer binding site in the leader region and b) the U3 and R regions from a Friend murine leukaemia virus (F-MuLV) as the U3 and R regions in the 3'-LTR and which are particularly suitable for an effective gene transfer in haematopoietic stem cells.
Inventors
- 👤 Christopher Baum
- 👤 Carol Stocking-Harbers
- 👤 Wolfram Ostertag
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 06:02
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; A; A61; A61P; A61P35/00; C07; C07K; C07K14/00; C07K14/435; C07K14/705; A61K; A61K48/00; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/13011; C12N2740/13041; C12N2740/13043
Claims Analysis
Total Claims: 35
Claim 1
Independent Claim
72 words
A retroviral vector hybrid comprising a) a 5'-LTR-comprising at least one U5 region or tRNA primer binding site wherein the region or site is selected from the group consisting of the U5 region of MESV, the tRNA primer binding site of MESV, the U5 region of MoMuSV, and the tRNA primer binding site of MoMuSV, and b) a 3'-LTR comprising the U3 and R regions from a Friend murine leukaemia virus (F-MuLV).
Claim 2
Dependent Claim
72 words
A retroviral vector hybrid comprising a) a 5'-LTR-comprising at least one U5 region or tRNA primer binding site wherein the region or site is selected from the group consisting of the U5 region of MESV, the tRNA primer binding site of MESV, the U5 region of MoMuSV, and the tRNA primer binding site of MoMuSV, and b) a 3'-LTR comprising the U3 and R regions from a Friend murine leukaemia virus (F-MuLV).
Claim 3
Dependent Claim
13 words
The vector hybrid of claim 1 further comprising the leader region of MESV.
Claim 4
Dependent Claim
35 words
The vector hybrid of claim 1, wherein the Friend murine leukaemia virus is selected from the group consisting of malignant histiosarcoma virus (MHSV), SFFVp Lilly-Steeves, SFFVa, Rauscher SSFV, F-muLVc157 and Friend-mink cell focus forming Virus.
Claim 5
Dependent Claim
26 words
The vector hybrid of claim 1, wherein the U3 and R regions in the 5'-LTR comprise the U3 and R regions from MPSV, MESV or PCMV.
Claim 6
Dependent Claim
16 words
The vector hybrid of claim 1, wherein the 5'-LTR comprises bp 142-657 from SEQ ID NO:1.
Claim 7
Dependent Claim
16 words
The vector hybrid of claim 1, wherein the 3'-LTR comprises bp 1707-2283 from SEQ ID NO:1.
Claim 8
Dependent Claim
26 words
The vector hybrid of claim 1 further comprising at least one gene that is heterologous to the retroviral vector and can be expressed in eukaryotic cells.
Claim 9
Dependent Claim
9 words
The vector hybrid of claim 1 which is replication-defective.
Claim 10
Dependent Claim
9 words
The vector hybrid of claim 1 which is replication-competent.
Claim 11
Dependent Claim
40 words
The vector hybrid of claim 7 wherein the heterologous gene is selected from the group consisting of a multiple drug resistance gene (MDR gene), an antibiotic resistance gene, a LNGFR gene, a cerebrosidase gene and the herpes simplex TK gene.
Claim 12
Dependent Claim
14 words
The vector of claim 10 wherein the heterologous gene is the neo R gene.
Claim 13
Dependent Claim
14 words
A vector hybrid selected from the group consisting of pSF1, pSF2, pSF3, and pHM1.
Claim 14
Dependent Claim
14 words
A vector hybrid selected from the group consisting of pSF1, pSF2, pSF3, and pHM1.
Claim 15
Dependent Claim
96 words
A process for the production of a retrovirally transduced eukaryotic cell which expresses an exogenous gene, said process comprising transducing a eukaryotic cell with a retroviral vector virus, which virus comprises a) at least one U5 region or tRNA primer binding site wherein the region or site is selected from the group consisting of the U5 region of MESV, the tRNA primer binding site of MESV, the U5 region of MoMuSV, and the tRNA primer binding site of MoMuSV, and b) a 3'-LTR comprising the U3 and R regions from a Friend murine leukaemia virus (F-MuLV).
Claim 16
Dependent Claim
96 words
A process for the production of a retrovirally transduced eukaryotic cell which expresses an exogenous gene, said process comprising transducing a eukaryotic cell with a retroviral vector virus, which virus comprises a) at least one U5 region or tRNA primer binding site wherein the region or site is selected from the group consisting of the U5 region of MESV, the tRNA primer binding site of MESV, the U5 region of MoMuSV, and the tRNA primer binding site of MoMuSV, and b) a 3'-LTR comprising the U3 and R regions from a Friend murine leukaemia virus (F-MuLV).
Claim 17
Dependent Claim
15 words
The process as claimed in claim 13 wherein the retroviral vector virus is replication defective.
Claim 18
Dependent Claim
16 words
The process as claimed in claim 13 wherein the eukaryotic cells is a haematopoietic stem cells.
Claim 19
Dependent Claim
83 words
An eukaryotic cell obtained by the process of transducing a eukaryotic cell with a retroviral vector virus comprising a) at least one U5 region or tRNA primer binding site wherein the region or site is selected from the group consisting of the U5 region of MESV, the tRNA primer binding site of MESV, the U5 region of MoMuSV, and the tRNA primer binding site of MoMuSV, and b) a 3'-LTR comprising the U3 and R regions from a Friend murine leukaemia virus (F-MuLV).
Claim 20
Dependent Claim
83 words
An eukaryotic cell obtained by the process of transducing a eukaryotic cell with a retroviral vector virus comprising a) at least one U5 region or tRNA primer binding site wherein the region or site is selected from the group consisting of the U5 region of MESV, the tRNA primer binding site of MESV, the U5 region of MoMuSV, and the tRNA primer binding site of MoMuSV, and b) a 3'-LTR comprising the U3 and R regions from a Friend murine leukaemia virus (F-MuLV).
Claim 21
Dependent Claim
31 words
The cell of claim 16 wherein the F-MuLV is selected from the group consisting of malignant histiosarcoma virus (MHSV), SFFVp Lilly-Steeves, SFFVa, Rauscher SSFV, F-muLVc157 and Friend-mink cell focus forming virus.
Claim 22
Dependent Claim
15 words
The cell of claim 16 wherein the vector further comprises the leader region of MESV.
Claim 23
Dependent Claim
13 words
The cell of claim 16 wherein the retroviral vector virus is replication defective.
Claim 24
Dependent Claim
106 words
A replication defective infectious virus particle comprising a retroviral RNA genome, wherein the genome comprises a) at least one U5 region or tRNA primer binding site selected from the group consisting of the U5 region of MESV, the tRNA primer binding site of MESV, the U5 region of MoMuSV, and the tRNA primer binding site of MoMuSV, and b) further comprises a packaging function, a gene which is heterologous to the virus and can be expressed in the eukaryotic cell, and U3 and R from a Friend murine leukaemia virus (F-MuLV), but c) does not comprise active gag, env and pol sequences at the 3' end.
Claim 25
Dependent Claim
106 words
A replication defective infectious virus particle comprising a retroviral RNA genome, wherein the genome comprises a) at least one U5 region or tRNA primer binding site selected from the group consisting of the U5 region of MESV, the tRNA primer binding site of MESV, the U5 region of MoMuSV, and the tRNA primer binding site of MoMuSV, and b) further comprises a packaging function, a gene which is heterologous to the virus and can be expressed in the eukaryotic cell, and U3 and R from a Friend murine leukaemia virus (F-MuLV), but c) does not comprise active gag, env and pol sequences at the 3' end.
Claim 26
Dependent Claim
145 words
A process for the production of a replication defective infectious virus particle comprising a) transfecting a eukaryotic helper cell which has the helper functions gag, env and pol with a vector hybrid comprising i) at least one U5 region or tRNA primer binding site wherein the region or site is selected from the group consisting of the U5 region of MESV, the tRNA primer binding site of MESV, the U5 region of MoMuSV, and the tRNA primer binding site of MoMuSV, and ii) a 3'-LTR comprising the U3 and R regions from a Friend murine leukaemia virus (F-MuLV), b) producing the RNA corresponding to the DNA of the vector hybrid as the virus genome in the cell, c) packaging the virus genome into the replication deficient empty virus envelopes formed in the cell, and d) isolating the infectious virus particles which contain said virus genome.
Claim 27
Dependent Claim
145 words
A process for the production of a replication defective infectious virus particle comprising a) transfecting a eukaryotic helper cell which has the helper functions gag, env and pol with a vector hybrid comprising i) at least one U5 region or tRNA primer binding site wherein the region or site is selected from the group consisting of the U5 region of MESV, the tRNA primer binding site of MESV, the U5 region of MoMuSV, and the tRNA primer binding site of MoMuSV, and ii) a 3'-LTR comprising the U3 and R regions from a Friend murine leukaemia virus (F-MuLV), b) producing the RNA corresponding to the DNA of the vector hybrid as the virus genome in the cell, c) packaging the virus genome into the replication deficient empty virus envelopes formed in the cell, and d) isolating the infectious virus particles which contain said virus genome.
Claim 28
Dependent Claim
32 words
The process of claim 21 wherein the F-MuLV is selected from the group consisting of malignant histiosarcoma virus (MHSV), SFFVp Lilly-Steeves, SFFVa, Rauscher SFFV, F-muLVc 157 and Friend-mink cell focus forming virus.
Claim 29
Dependent Claim
16 words
The process of claim 21 wherein the vector hybrid further comprises the leader region of MESV.
Claim 30
Dependent Claim
51 words
A retroviral vector hybrid comprising a) the U5 region and tRNA primer binding site of MESV as the U5 region and the tRNA primer binding site in the leader region, and b) the U3 and R regions from myeloproliferative sarcoma virus (MPSV) as the U3 and R regions in the 3'-LTR.
Claim 31
Dependent Claim
51 words
A retroviral vector hybrid comprising a) the U5 region and tRNA primer binding site of MESV as the U5 region and the tRNA primer binding site in the leader region, and b) the U3 and R regions from myeloproliferative sarcoma virus (MPSV) as the U3 and R regions in the 3'-LTR.
Claim 32
Dependent Claim
77 words
A process for the production of a retrovirally transduced eukaryotic cell comprising an exogenous gene, wherein the eukaryotic cell is transduced with the retroviral vector virus comprising: a) the U5 region and/or tRNA primer binding site of MESV as the U5 region and/or tRNA primer binding site in the leader region, b) the U3 and R regions from myeloproliferative sarcoma virus (MPSV) as the U3 and R regions in the 3'-LTR and c) the said exogenous gene.
Claim 33
Dependent Claim
77 words
A process for the production of a retrovirally transduced eukaryotic cell comprising an exogenous gene, wherein the eukaryotic cell is transduced with the retroviral vector virus comprising: a) the U5 region and/or tRNA primer binding site of MESV as the U5 region and/or tRNA primer binding site in the leader region, b) the U3 and R regions from myeloproliferative sarcoma virus (MPSV) as the U3 and R regions in the 3'-LTR and c) the said exogenous gene.
Claim 34
Dependent Claim
77 words
A replication defective infectious virus particle comprising retroviral RNA as the genome, wherein the genome comprises the U5 regions and/or tRNA primer binding site of MESV as the U5 region and/or tRNA primer binding site, a packaging function and a gene which is heterologous for the virus and can be expressed in the eukaryotic cell, and U3 and R from the myeloproliferative sarcoma virus (MPSV) but no active gag, env and pol sequences at the 3' end.
Claim 35
Dependent Claim
77 words
A replication defective infectious virus particle comprising retroviral RNA as the genome, wherein the genome comprises the U5 regions and/or tRNA primer binding site of MESV as the U5 region and/or tRNA primer binding site, a packaging function and a gene which is heterologous for the virus and can be expressed in the eukaryotic cell, and U3 and R from the myeloproliferative sarcoma virus (MPSV) but no active gag, env and pol sequences at the 3' end.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-01-11 | 2002-07-13 | 2003-01-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-01-11 | 2006-07-13 | 2007-01-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-01-11 | 2010-07-13 | 2011-01-12 | $7700.00 | Window Closed / Lapsed |